|
| 37551156 | Giving information strategically and transparently: A pilot trial of the Oncolo-GIST intervention to promote patients' prognostic understanding. | Cancer Med | 2023 |
| 34417914 | A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. | Invest New Drugs | 2022 |
| 35652416 | Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. | J Thromb Haemost | 2022 |
| 35499204 | A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. | Cancer Med | 2022 |
| 35323123 | Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. | JMIR Cancer | 2022 |
| 34029423 | Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. | Ann Neurol | 2021 |
| 33741442 | Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. | Ann Oncol | 2021 |
| 34625409 | Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. | Cancer Prev Res (Phila) | 2021 |
| 34168263 | Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. | Commun Biol | 2021 |
| 32641434 | Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. | Clin Cancer Res | 2020 |
| 31592503 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. | JCO Precis Oncol | 2019 |
| 31559379 | A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus <i>nab</i>-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. | J Pancreat Cancer | 2019 |
| 31510897 | Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. | Stroke | 2019 |
| 29545721 | Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-systems approach to cancer therapy (U.S. FDA IND-BB 10091; NCT 02046174, NCT 01053013). | Chin J Cancer Res | 2018 |
| 29853643 | Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. | Cancer Discov | 2018 |
| 27836862 | Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. | Clin Cancer Res | 2017 |
| 28291390 | Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. | J Clin Oncol | 2017 |
| 28558150 | Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. | Cancer | 2017 |
| 28548889 | Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. | J Clin Oncol | 2017 |
| 28679770 | Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. | Clin Cancer Res | 2017 |
| 27499645 | First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors. | Cancer Growth Metastasis | 2016 |
| 26541586 | Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. | Clin Genitourin Cancer | 2016 |
| 27362999 | Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. | Eur J Cancer | 2016 |
| 25985394 | Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. | Nat Cell Biol | 2015 |
| 26438119 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. | J Clin Oncol | 2015 |
| 26187510 | (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. | Eur J Cancer | 2015 |
| 25924227 | Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. | Nat Commun | 2015 |
| 25944802 | First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. | Clin Cancer Res | 2015 |
| 24526575 | Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. | Invest New Drugs | 2014 |
| 22569804 | Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. | Cancer | 2012 |
| 20981545 | Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. | Cancer Chemother Pharmacol | 2011 |
| 22114576 | Isolated splenic metastasis from rectal carcinoma: a rare occurrence. | Case Rep Oncol | 2011 |
| 21569993 | Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. | Clin Breast Cancer | 2011 |
| 19738452 | Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. | Am J Clin Oncol | 2010 |
| 21208843 | Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. | Clin Colorectal Cancer | 2010 |
| 19738454 | A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. | Am J Clin Oncol | 2010 |
| 18565886 | Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. | J Clin Oncol | 2008 |
| 15258838 | Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. | Support Care Cancer | 2004 |